Antiretroviral Treatment of HIV/AIDS During Pregnancy

Ahizechukwu C Eke; Shahin Lockman; Lynne M Mofenson

doi:10.1001/jama.2023.5076

Antiretroviral Treatment of HIV/AIDS During Pregnancy

JAMA. 2023 Apr 18;329(15):1308-1309. doi: 10.1001/jama.2023.5076.

Authors

Ahizechukwu C Eke^{1

2}, Shahin Lockman^{3

4

5}, Lynne M Mofenson⁶

Affiliations

¹ Division of Maternal Fetal Medicine, Department of Gynecology & Obstetrics, Johns Hopkins University School of Medicine, Baltimore, Maryland.
² Division of Clinical Pharmacology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
³ Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts.
⁴ Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
⁵ Botswana Harvard Health Partnership, Gaborone, Botswana.
⁶ Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC.

No abstract available

Plain language summary

This Insights in the Women’s Health series describes the availability, timing, and risks of antiretroviral therapy (ART) in pregnant individuals who have HIV infection.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Acquired Immunodeficiency Syndrome / drug therapy
Anti-HIV Agents* / therapeutic use
Anti-Retroviral Agents / therapeutic use
Female
HIV Infections* / drug therapy
Humans
Infectious Disease Transmission, Vertical / prevention & control
Pregnancy
Pregnancy Complications, Infectious* / drug therapy

Substances

Anti-HIV Agents
Anti-Retroviral Agents

Plain language summary

Publication types

MeSH terms

Substances

Grants and funding